Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)

v3.22.0.1
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Net sales $ 269,276 $ 224,253 $ 526,995 $ 428,452
Cost of sales 85,585 73,353 172,307 139,821
Gross margin 183,691 150,900 354,688 288,631
Operating expenses:        
Selling, general and administrative 100,693 83,116 186,868 155,714
Research and development 20,650 16,789 42,250 32,830
Total operating expenses 121,343 99,905 229,118 188,544
Operating income 62,348 50,995 125,570 100,087
Other income (expense) 23,831 5,373 27,992 (4,381)
Earnings before income taxes 86,179 56,368 153,562 95,706
Income taxes (benefit) 14,120 10,224 12,522 16,168
Net earnings, including noncontrolling interest 72,059 46,144 141,040 79,538
Net earnings (loss) attributable to noncontrolling interest (8,114) (130) (8,748) (130)
Net earnings attributable to Bio-Techne 80,173 46,274 149,788 79,668
Other comprehensive income (loss):        
Foreign currency translation adjustments 1,924 16,928 (6,722) 28,842
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 2,884 2,059 4,566 4,202
Other comprehensive income (loss) 4,808 18,987 (2,156) 33,044
Other comprehensive income (loss) attributable to noncontrolling interest 66 83 27 83
Other comprehensive income (loss) attributable to Bio-Techne 4,742 18,904 (2,183) 32,961
Comprehensive income attributable to Bio-Techne $ 84,915 $ 65,178 $ 147,605 $ 112,629
Earnings per share attributable to Bio-Techne:        
Basic (in dollars per share) $ 2.04 $ 1.20 $ 3.82 $ 2.06
Diluted (in dollars per share) $ 1.94 $ 1.15 $ 3.64 $ 1.98
Weighted average common shares outstanding:        
Basic (in shares) 39,310 38,691 39,202 38,614
Diluted (in shares) 41,207 40,257 41,159 40,135